Private capital allocation across the global healthcare and life sciences landscape reached an unprecedented structural inflection point during the first half of 2026. Driven by ongoing institutional portfolio rebalancing, prolonged liquidity constraints and shifting reimbursement fundamentals, the market has bifurcated into a high concentration fundraising environment alongside an acute divergence in sub-sector investment performance.